^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    STLA101 Test

    Company:
    Stella Diagnostics
    Type:
    Laboratory Developed Test
    Details
    Evidence

    News

    over2years
    Stella Diagnostics and Mayo Clinic to present data on the utility of the STLA101 Test for esophageal cancer staging at the 2022 AGA Digestive Disease Week Conference (GlobeNewswire)
    "Stella Diagnostics, Inc...announced today that its abstract titled 'Markers in STLA101 Assay Detects Differential Expression to Distinguish Between Intramucosal and Invasive Esophageal Adenocarcinoma' has been selected for presentation during Digestive Disease Week (DDW) 2022, which will take place May 21–24, 2022 at the San Diego Convention Center in San Diego, CA."
    Clinical data
    |
    STLA101 Test
    over2years
    MARKERS IN STLA101 ASSAY DETECTS DIFFERENTIAL EXPRESSION TO DISTINGUISH BETWEEN INTRAMUCOSAL AND INVASIVE ESOPHAGEAL ADENOCARCINOMA (DDW 2022)
    A large percentage of EAC histologic specimens do not show sufficient tissue depth to distinguish IMC from iEAC. Here, we show that molecular diagnostics via mass spectrometry may aid in characterizing the depth of invasion, when paired with histology.
    S100P (S100 calcium binding protein P)
    |
    STLA101 Test